142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

297756
Minimizing Dual-Eilgible Beneficiaries Out-of-Pocket Prescription Drug Costs: A Paradigm Shift

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 9:00 AM - 9:15 AM

Rajul A. Patel, PharmD, PhD , Department of Pharmacy Practice, School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Yvi Le, Pharm.D. Student , School of Pharmacy & Health Sciences, University of the Pacific, Stockton, CA
Kristin Dang, Pharm.D. Student , School of Pharmacy & Health Sciences, University of the Pacific, Stockton, CA
Thi Vu, Pharm.D. Student , School of Pharmacy & Health Sciences, University of the Pacific, Stockton, CA
Anna Cho, Pharm.D. Student , School of Pharmacy & Health Sciences, University of the Pacific, Stockton, CA
Mark P. Walberg, PharmD, PhD , Department of Pharmacy Practice, School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Joseph A. Woelfel, PhD, RPh , Department of Pharmacy Practice, School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Background: Medicare beneficiaries receive prescription drug coverage through Part D and those with limited income/resources receive additional governmental assistance through Medicaid (Medi-Cal in California). For these dual-eligible beneficiaries, Part D is the primary payer and Medicaid can be billed secondarily when medications are not on the beneficiary’s Part D plan formulary. As opposed to having co-pays when billed through their Part D plan, dual-eligible beneficiaries are not responsible for drug co-pays when billed through Medi-Cal. We examined potential out-of-pocket costs savings through: 1) Part D plan optimization and 2) strategic utilization of existing formularies (Part D plan and Medi-Cal).

Methods: We assisted 151 dual-eligible beneficiaries with their Part D plan in Northern/Central California in fall 2013. In addition to determining the lowest cost Part D plan, we examined if beneficiaries’ out-of-pocket costs could be further reduced by selecting an alternative plan under which their medication(s) was non-formulary but covered by Medi-Cal.

Results: Dual-eligible beneficiaries could annually save an average (SD) of $1174 ($3286) through Part D plan optimization. In 44 (27.8%) instances, beneficiaries could save additional money (Mean + SD: $107+281) through Part D and Medi-Cal formulary optimization. Each time, the lowest cost plan was a benchmark plan.

Conclusions: Dual-eligible beneficiaries have incomes <100% of the Federal Poverty Line. Research has shown that as out-of-pocket costs increase so too does medication non-adherence. Aside from Part D plan optimization, we identified a novel approach that can be utilized to help further lower out-of-pocket prescription drug costs in the vulnerable dual-eligible beneficiary population.

Learning Areas:

Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
Describe a novel approach to assisting dual-Eligible (Medicare + Medicaid)beneficiaries with their out-of-pocket prescription drug costs. Demonstrate the absolute and relative potential cost-savings opportunities resulting from a change in the way that dual-eligible beneficiaries are assisted with the Part D plan.

Keyword(s): Policy/Policy Development, Health Care Costs

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have worked with Medicare beneficiaries helping them optimize their Part D benefit for the last 7 years. In that time I have presented over 60 posters and podium talks at national/international meetings on various aspects of the Part D benefit. I have also published extensively in this arena.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 5025.0: Medicare and Medicaid Policy